Mogroside III-E

Overview

Mogroside III-E is a cucurbitane-type triterpenoid glycoside extracted from Siraitia grosvenorii , and it is an orally active TLR4 inhibitor. Mogroside III-E downregulates the expression of TLR4 and MyD88 , and blocks the phosphorylation of downstream ERK , JNK and p38 MAPK molecules; meanwhile, it inhibits TGF-β- or LPS-mediated transdifferentiation of primary pulmonary fibroblasts into myofibroblasts, reduces the content of fibrosis markers such as hydroxyproline, suppresses the pro-fibrotic TGF-β/Smad signaling pathway, and downregulates the levels of inflammatory factors MPO and IL-1β . Mogroside III-E alleviates Bleomycin ( HY-108345 )-induced pulmonary collagen deposition and inflammatory infiltration in mice. Mogroside III-E can be used in studies related to idiopathic pulmonary fibrosis.

Application

Products | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Lung Fibrosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > TGF-β Receptor | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > Toll-like Receptor (TLR) | Products > Signaling Pathways > ERK | Products > Signaling Pathways > JNK | Products > Signaling Pathways > p38 MAPK

Product Information

• Catalog No.: HY-N6928
• CAS No.: 88901-37-5
• Molecular Formula: C48H82O19
• Molecular Weight: 963.15
• Purity: 99.30%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2.5 mg/mL (2.60 mM); Clear solution
• Availability: In-stock

Source

Original product source